Navigation Links
Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited
Date:3/28/2011

FRAZER, Pa. and MELBOURNE, Australia, March 28, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) and ChemGenex Pharmaceuticals Limited (ASX: CXS) today jointly announced that Cephalon's wholly-owned subsidiary, Cephalon CXS Holdings Pty Ltd, intends to make a takeover bid for ChemGenex. ChemGenex is a hematology-focused Australian biopharmaceutical company developing its lead product candidate, OMAPRO™, for the treatment of chronic myeloid leukemia (CML) patients.  OMAPRO recently completed Phase III clinical trials and ChemGenex plans to file a New Drug Application with the U.S. Food and Drug Administration in the second half of 2011.

The takeover bid has the unanimous support of the ChemGenex Directors who will recommend it to ChemGenex Shareholders in the absence of a superior offer.

In October 2010, Cephalon, through its wholly-owned subsidiary, Cephalon International Holdings, Inc. (Cephalon International) agreed to subscribe for A$15 million of convertible notes issued by ChemGenex and entered into call option agreements with two of ChemGenex's major shareholders, Stragen International N.V. and Merck Sante S.A.S.  ChemGenex shareholders gave advance approval to the conversion of the convertible notes (in accordance with item 7 of section 611 of the Corporations Act) at a general meeting held in December 2010.

Cephalon International has today served notice to convert its convertible notes and exercise its call options to acquire in aggregate 86.4 million ChemGenex Shares.  This will result in Cephalon International holding in total 27.57 percent of the issued ChemGenex Shares.

Cephalon's takeover bid for ChemGenex will comprise two offers:

  • an offer of A$0.70 cash for each ChemGenex Share (ASX: CXS), cum dividends and other rights; and

  • an offer of A$0.02 cash for each ASX-listed ChemGenex Option (ASX: CXSOA)
    '/>"/>

  • SOURCE Cephalon, Inc.; ChemGenex Pharmaceuticals Limited
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. Cephalon Wins FENTORA Patent Suit Against Watson
    2. Cephalon Announces Definitive Agreement to Acquire Gemin X
    3. Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010
    4. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
    5. ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
    6. Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder
    7. Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
    8. Cephalon to Webcast Investor Day
    9. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
    10. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
    11. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- Market Research Report ... 2009-2019 is a professional and in-depth market survey ... industry . The report firstly reviews the basic ... application and manufacturing technology. The report then explores ... Scanner listing their product specification, capacity, Production value, ...
    (Date:8/29/2014)... 2014 The clinical and medical insights provided ... between a product,s success or failure. Despite this, many ... targets – and then to coordinate activities and outreach ... upon which successful KOL engagement rests. ... internal inconsistencies in their KOL management systems and are ...
    (Date:8/29/2014)... 29, 2014 /PRNewswire-iReach/ -- SAM Medical Products Implements ... the SAM Junctional Tourniquet.  Photo ... Medical Products announced today that it has begun ... a potential issue with a clip used to ... application of the SAM Junctional Tourniquet (SJT).  The ...
    Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5Implementing a Strategic Thought Leader Management & Engagement System 2SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2
    ... , GLENWOOD, Ill., Nov. 20 /PRNewswire-FirstCall/ -- ... release financial results for the fiscal fourth quarter and full ... The company will host a conference call for investors on ... may access the live call by dialing 877-941-9205 (within the ...
    ... , HARRISBURG, Pa., Nov. 20 The Department of Health ... that did not have previous access to the vaccine. , A total ... hours are from 2 p.m. to 8 p.m. Hours on Saturday, Nov. ... the clinics will operate from 2 p.m. to 8 p.m. , ...
    Cached Medicine Technology:Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results 2Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available 2
    (Date:9/1/2014)... Texas (PRWEB) September 02, 2014 “Australia ... data on the Australia Hernia Repair market. The report ... units) and average prices (in US dollars) within market ... Meshes and Synthetic 3D Meshes) ,     Composite Meshes ... to a surgical operation for the correction of a ...
    (Date:9/1/2014)... with action and sound may be bad for your ... grapes while watching an excerpt from a Hollywood action ... Television has been blamed for helping Americans to gain ... focus of why has been on the medium and ... that can cause people to eat more, including reading, ...
    (Date:9/1/2014)... Reinberg HealthDay Reporter ... head-to-head comparison, an experimental drug was more effective than ... failure patients. According to the study authors, the ... of the new drug, dubbed LCZ696. In ... medication, enalapril (Vasotec), either died or were hospitalized due ...
    (Date:9/1/2014)... York (PRWEB) September 01, 2014 Liver is ... one vital organ that helps the body in barring itself ... a store of energy. Liver also plays many important functions ... iron and glucose. , Many illnesses can affect the ... under the rib cage on the right side of the ...
    (Date:9/1/2014)... (PRWEB) September 01, 2014 More than ... added to a federal litigation that continues to progress ... Bernstein Liebhard LLP reports. , A federal Case ... filed over the widely-used cholesterol medication by plaintiffs who ... According to claims, Pfizer Inc. failed to adequately warn ...
    Breaking Medicine News(10 mins):Health News:Australia Hernia Repair Market (Synthetic, Composite and Biological Meshes) Outlook to 2020 Report Available at MarketOptimizer.org 2Health News:Australia Hernia Repair Market (Synthetic, Composite and Biological Meshes) Outlook to 2020 Report Available at MarketOptimizer.org 3Health News:Australia Hernia Repair Market (Synthetic, Composite and Biological Meshes) Outlook to 2020 Report Available at MarketOptimizer.org 4Health News:Research letter: Viewers ate more while watching Hollywood action flick on TV 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 2Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3
    ... The infant mortality rate in Orissa would continue to soar ... Suni Naik’s family is still trying to recover after losing ... delivery. // ,Speaking at Talchampei village in tribal-dominated Keonjhar ... They suffered from fever. I took Rs.1,000 from a moneylender ...
    ... A report published in the January/February issue of General ... journal, says that most children's medicines have the potential ... sugar in them. // ,For example, antihistamine syrups ... low pH levels, which mean that they are high ...
    ... it has been shown that tomato juice prevented emphysema in ... of the lung-destroying disease. // ,The lung protective ... ,This study appears to be the first to link tomato ... by the researchers, 'We can't simply accept that these results ...
    ... is greatly increased if an individual has a variant form ... tongue // . The taste receptor gene, called TAS2R16 is ... Washington University School of Medicine have studied more than 262 ... family participated in a study called Collaborative Study of the ...
    ... his team from University of California, San Francisco using ... sickle cell anemia // in bioengineered mice with healthy ... genes, after therapy it was found that the replaced ... published their work in the Journal Proceedings of the ...
    ... Department of Health and Human Services reported that very little ... of the illness (bird flu) // . The infection in ... avian influenza. ,Hence to prevent the global pandemic ... of an occurrence of a global pandemic. The government ...
    Cached Medicine News:Health News:Poverty Claims Valuable Lives Of Children In Orissa 2Health News:Genetic Variation In Bitter-Taste Receptor Gene Increases Alcoholic Risk 2